title: Isolated regional therapy for advanced extremity soft tissue sarcomas.
abstract: Patients presenting with unresectable, large, primary or recurrent extremity soft tissue sarcoma or locally advanced extremity tumors may benefit from treatment options in the form of isolated regional perfusion therapy. Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) have proved to be efficacious with acceptable systemic and regional toxicity profiles. Both procedures are attractive as options for patients who might otherwise be facing amputation as limb salvage procedures. HILP and ILI can be offered as either definitive treatment or as neoadjuvant therapy followed by surgery and/or radiation treatment. Response rates are encouraging as are limb preservation rates after regional therapy. Ongoing multicenter collaborations and clinical trials are required to gain knowledge on HILP and ILI for unresectable extremity sarcoma and expand the indications for use in the management of advanced extremity soft tissue sarcoma.
authors.affiliation: Cutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL 33612, USA.
authors.forename: Jeremiah L
authors.initials: JL
authors.lastname: Deneve
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Zager
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods*; D005121:Extremities; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D059351:Organ Sparing Treatments / Q000379:methods; D010166:Palliative Care / Q000379:methods; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents